Reply to: “Serum HBV pgRNA as a clinical marker for cccDNA activity”: Consistent loss of serum HBV RNA might predict the “para-functional cure” of chronic hepatitis B

Journal of Hepatology

Volumn 66, Issue 2, 2017, Pages 462-463

  Wang, Jie ^a   Du, Man ^b   Huang, Hongxin ^a   Chen, Ran ^a   Niu, Junqi ^c   Jiang, Jianning ^b   Zhuang, Hui ^a   Lu, Fengmin ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

^c THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CIRCULAR DNA; CLOSED CIRCULAR DNA; HEPATITIS B(E) ANTIGEN; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PEGINTERFERON ALPHA; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA; HEPATITIS B SURFACE ANTIGEN; PGRNA; RNA;

BLOOD LEVEL; CHRONIC HEPATITIS B; DNA TRANSCRIPTION; HEPATITIS B VIRUS; HUMAN; LETTER; LIMIT OF DETECTION; NONHUMAN; PRIORITY JOURNAL; SUSTAINED VIROLOGIC RESPONSE; GENETICS; VIRUS REPLICATION;

BIOMARKERS; DNA, CIRCULAR; DNA, VIRAL; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; RNA; VIRUS REPLICATION;

EID: 85006964816     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.10.034     Document Type: Letter

References (9)

1. [1] Wang, J., Shen, T., Huang, X., Kumar, G.R., Chen, X., Zeng, Z., et al. Serum hepatitis B virus is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol 65 (2016), 700–710.
2. [2] Giersch, K., Allweiss, L., Volz, T., Dandri, M., Lütgehetmann, M., Serum HBV pgRNA as a clinical marker for cccDNA activity. J Hepatol 66 (2017), 460–462.
3. [3] Li, W., Zhao, J., Zou, Z., Liu, Y., Li, B., Sun, Y., et al. Analysis of hepatitis B virus intrahepatic covalently closed circular DNA and serum viral markers in treatment-naïve patients with acute and chronic HBV infection. PLoS One, 9, 2014, e89046.
4. [4] Petersen, J., Thompson, A.J., Levrero, M., Aiming for cure in HBV and HDV infection. J Hepatol 65 (2016), 835–848.
5. [5] The guideline of prevention and treatment for chronic hepatitis B: a 2015 update. Zhonghua Gan Zang Bing Za Zhi 2015 (2015), 888–905.
6. [6] EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57 (2012), 167–185.
7. [7] Jiang, S., Yang, Z., Li, W., Li, X., Wang, Y., Zhang, J., et al. Re-evaluation of the carcinogenic significance of hepatitis B virus integration in hepatocarcinogenesis. PLoS One, 7, 2012, e40363.
8. [8] Li, X., Zhang, J., Yang, Z., Kang, J., Jiang, S., Zhang, T., et al. The function of targeted host genes determines the oncogenicity of HBV integration in hepatocellular carcinoma. J Hepatol 60 (2014), 975–984.
9. [9] Mason, W.S., Gill, U.S., Litwin, S., Zhou, Y., Peri, S., Pop, O., et al. HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant. Gastroenterology, 2016, 10.1053/j.gastro.2016.07.012 pii: S0016-5085(16)34808-9 [Epub ahead of print].